REMODELING OF THE LEFT VENTRICLE: ONE OR SEVERAL SCENARIOS?
V. V. Kalyuzhin,
A. T. Teplyakov,
M. A. Solovtsov,
E. V. Kalyuzhina,
I. D. Bespalova,
N. N. Terentyeva https://doi.org/10.20538/1682-0363-2016-4-120-139
Abstract
The authors of the review have analyzed papers published on the problem of remodeling of the left ventricle (LV), which is in accordance with a consensus paper from an International Forum on Cardiac Remodeling may be defined as genome expression, molecular, cellular and interstitial changes that are manifested clinically as changes in size, shape and function of the LV after cardiac injury. Remodeling of the LV is often seen as a nonspecific process independent of the nature of the underlying disease (cluster of disease). This approach, contrary to the theory of multimodal response of the myocardium (myocytes and interstitium) on the molecular-genetic, cellular, tissue, and organ levels, largely depending on the nature and duration of the triggering factor, as well as modern ideas about the types of LV remodeling and dividing the latter into serdechadaptive and non-adaptive forms, was the subject of legitimate criticism. Analyzed scenarios the molecular and cellular events, as well as deals with diagnosis of left ventricular remodeling. Discusses the classification of LV remodeling.
About the Authors
V. V. Kalyuzhin
Siberian State Medical University 2, Moscow Trakt, Tomsk, 634050, Russian Federation
Russian Federation
Russian Federation
MD, Professor of the Department of Hospital Therapy with a Сourse of Physical Rehabilitation and Sports Medicine, Siberian State Medical University, Tomsk, Russian Federation
A. T. Teplyakov
Research Institute of Cardiology 111а, Kievskaya St., 634012, Tomsk, Russian Federation
Russian Federation
Russian Federation
MD, Professor, Head of the Department of Heart Failure, Research Institute for Cardiology, Tomsk, Russian Federation
M. A. Solovtsov
Regional Clinical Hospital 96, I. Chernuh St., Tomsk, 634063, Russian Federation
Russian Federation
Russian Federation
Doctor of the Department of Ultrasonic Diagnostics, Regional Clinical Hospital, Tomsk, Russian Federation
E. V. Kalyuzhina
Siberian State Medical University 2, Moscow Trakt, Tomsk, 634050, Russian Federation
Russian Federation
Russian Federation
MD, Professor of the Department of Hospital Therapy with a Сourse of Physical Rehabilitation and Sports Medicine, Siberian State Medical University, Tomsk, Russian Federation
I. D. Bespalova
Siberian State Medical University 2, Moscow Trakt, Tomsk, 634050, Russian Federation
Russian Federation
Russian Federation
PhD, Head of the Department of Social Work, Social and Clinical Psychology, Siberian State Medical University, Tomsk, Russian Federation
N. N. Terentyeva
Surgut State University 1, Lenina Av., Surgut, 628412, Russian Federation
Russian Federation
Russian Federation
PhD, Associate Professor of the Department of Hospital Therapy, Surgut State University, Surgut, Russian Federation
References
1. Vasilenko V.H. Nedostatochnost’ krovoobrashhenija [Circulatory failure] / Bol’shaja medicinskaja jenciklopedija [The big medical encyclopedia]; Ed. 2. / ed. by A.N. Bakulev, Moscow, Soviet encyclopedia Publ., 1960; 14: 543–604 (in Russian).
2. Chazov E.I. Spornye voprosy v probleme hronicheskoj serdechnoj nedostatochnosti [Controversial issues in the problem of chronic heart failure] // Terapevticheskiy Arkhiv - Therapeutic archive. 1993; 9: 4–7 (in Russian).
3. Malaja L.T., Gorb Ju.G. Hronicheskaja serdechnaja nedostatochnost’: Novejshij spravochnik [Chronic heart failure: the Newest guide], Moscow, Eksmo Publ., 2004: 960 p. (in Russian).
4. Yap J., Lim F.Y., Gao F., Teo L.L., Lam C.S., Yeo K.K. Correlation of the New York Heart Association Classification and the 6-Minute Walk Distance: A Systematic Review // Clin. Cardiol. 2015; 38 (10): 621–628. doi: 10.1002/clc.22468.
5. Dzau V.J., Antman E.M., Black H.R., Hayes D.L., Manson J.E., Plutzky J., Popma J.J., Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes. Part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) // Circulation. 2006; 114: 2850–2870.
6. Belenkov Ju.N., Mareev V.Ju. Serdechno-sosudistyj kontinuum [The cardiovascular continuum] // Zhurnal serdechnaja nedostatochnost’. 2002; 1: 7–11 (in Russian).
7. Ageev F.T., Ovchinnikov A.G. Diastolicheskaja disfunkcija kak projavlenie remodelirovanija serdca [Diastolic dysfunction as a manifestation of cardiac remodeling] // Zhurnal serdechnaja nedostatochnost’. 2002; 4: 190–195 (in Russian).
8. Burchfield J.S., Xie M., Hill J.A. Pathological Ventricular Remodeling. Mechanisms: Part 1 of 2 // Circulation. 2013; 128: 388–400.
9. Teplyakov A.T., Kalyuzhin V.V. Remodelirovanie serdca: svjaz’ s razvitiem sistolicheskoj i diastolicheskoj disfunkciej [Cardiac remodeling: correlation with the development of systolic and diastolic dysfunction] / Koronarnaja i serdechnaja nedostatochnost’: kollektivnaja monografija [Coronary and heart failure: a collective monograph] / ed. by R.S. Karpov, Tomsk: STT Publ., 2005: 229–232 (in Russian).
10. Kobirumaki-Shimozawa F., Inoue T., Shintani S.A., Oyama K., Terui T., Minamisawa S., Ishiwata S., Fukuda N. Cardiac thin filament regulation and the Frank-Starling mechanism // J. Physiol. Sci. 2014; 64 (4): 221–32. doi: 10.1007/s12576-014-0314-y.
11. Weisman H.F., Bush D.E., Mannisi J.A., Bulkley B.H. Global cardiac remodeling after acute myocardial infarction: a study in the rat model // J. Am. Coll. Cardiol. 1985; 5 (6): 1355–1362.
12. McKay R.G., Pfeffer M.A., Pasternak R.C., Markis J.E., Come P.C., Nakao S., Alderman J.D., Ferguson J.J., Safian R.D., Grossman W. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion // Circulation. 1986; 74 (4): 693–702.
13. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications // Circulation. 1990; 81 (4): 1161– 1172.
14. Florja V.G. Rol’ remodelirovanija levogo zheludochka v patogeneze hronicheskoj serdechnoj nedostatochnosti [The role of left ventricular remodeling in chronic heart failure pathogenesis] // Kardiologiya. 1997; 5: 63–67 (in Russian).
15. Spaich S., Katus H.A., Backs J. Ongoing controversies surrounding cardiac remodeling: is it black and white – or rather fifty shades of gray? // Frontiers in Physiology. 2015; 6: 202. doi: 10.3389/fphys.2015.00202. eCollection
16. Cohn J.N., Ferrari R., Sharpe N. on behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling – concepts and clinical implications: a consensus paper from an International Forum on Cardiac Remodeling // J. Am. Coll. Cardiol. 2000; 35 (3): 569–582.
17. Belenkov Ju.N. Remodelirovanie levogo zheludochka: kompleksnyj podhod [Remodeling of the left ventricle: an integrated approach] // Zhurnal serdechnaja nedostatochnost’. 2002; 3 (4): 161–163 (in Russian).
18. Xie M., Burchfield J.S., Hill J.A. Pathological ventricular remodeling: mechanisms: part 1 of 2 // Circulation. 2013; 128 (4): 388–400. doi:10.1161/CIRCULATIONAHA.113.001878.
19. Azevedo P.S., Polegato B.F., Minicucci M.F., Paiva S.A.R., Zornoff L.A.M. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment // Arq. Bras. Cardiol. 2016; 106 (1): 62–69. doi: 10.5935/abc.20160005
20. Kalyuzhin V.V., Kalyuzhin O.V., Teplyakov A.T., Karaulov A.V. Hronicheskaja serdechnaja nedostatochnost’ [Chronic heart failure ]. Moscow: Medical information agency Publ., 2006: 288 p. (in Russian).
21. Arutjunov G.P., Belenkov Ju.N., Vasjuk Ju.A., Mareev Ju.V., Sitnikova M.Ju., Fomin I.V. Hronicheskaja serdechnaja nedostatochnost’: rukovodstvo [Chronic heart failure: guide]. Moscow: GEOTAR-Media Publ., 2010: 336 (in Russian).
22. Hlapov A.P., Vecherskij Ju.Ju., Rjazanceva N.V., Kalyuzhin V.V., Mustafina L.R., Shipulin V.M., Novickij V.V. Rol’ apoptoza kardiomiocitov v mehanizmah ishemicheskogo remodelirovanija miokarda [The role of cardiomyocyte apoptosis in the mechanisms of ischemic myocardial remodeling] // Byulleten’ sibirskoy meditsiny – Bulletin of Siberian Medicine. 2008; 7 (3): 33–37. (in Russian).
23. Kalyuzhin V.V., Teplyakov A.T., Vecherskij Ju.Ju., Rjazanceva N.V., Hlapov A.P. P togenez hronicheskoj serdechnoj nedostatochnosti: izmenenie dominirujushhej paradigmy [The pathogenesis of chronic heart failure: the change in the dominant paradigm] // Byulleten’ sibirskoy meditsiny – Bulletin of Siberian Medicine. 2007; 6 (4): 71–79 (in Russian).
24. Kalyuzhin V.V., Teplyakov A.T., Kamaev D.Ju. Faktory, vlijajushhie na kachestvo zhizni bol’nyh, perenesshih infarkt miokarda [Factors affecting the quality of life of patients after myocardial infarction] // Kardiologiya, 2001; 41 (4): 58 (in Russian).
25. Heusch G., Libby P., Gersh B., Yellon D., Bцhm M., Lopaschuk G., Opie L. Cardiovascular remodelling in coronary artery disease and heart failure // Lancet. 2014; 383 (9932): 1933–1943. doi: 10.1016/S0140-6736(14)60107-0.
26. Kalyuzhin V.V., Teplyakov A.T., Rjazanceva N.V., Bespalova I.D., Kamaev D.Ju., Kalyuzhina E.V. Kachestvo zhizni bol’nyh ishemicheskoj bolezn’ju serdca, associirovannoj s metaboli-cheskim sindromom: rezul’taty faktornogo analiza [Quality of life in patients with ischemic heart disease associated with metabolic syndrome: results of factor analysis] // Terapevticheskiy Arkhiv – Therapeutic archive. 2012, vol. 84, no. 12, pp. 4–7 (in Russian).
27. Bespalova I.D., Medjancev Ju.A., Kalyuzhin V.V., Murashev B.Ju., Osihov I.A. Kachestvo zhizni bol’nyh gipertonicheskoj bolezn’ju s metabolicheskim sindromom [The quality of life of hypertensive patients with metabolic syndrome] // Arterial’naja gipertenzija. 2012; 18 (4): 304–309. (in Russian).
28. Kalyuzhin V.V., Teplyakov A.T., Solovcov M.A. Rol’ sistolicheskoj i diastolicheskoj disfunkcii levogo zheludochka v klinicheskoj manifestacii hronicheskoj serdechnoj nedostatochnosti u bol’nyh, perenesshih infarkt miokarda [The role of systolic and diastolic left ventricular dysfunction to clinical manifestations of chronic heart failure in patients after myocardial infarction] // Terapevticheskiy Arkhiv – Therapeutic archive. 2002; 74 (12): 15–18 (in Russian).
29. Genet M., Lee L.C., Baillargeon B., Guccione J.M., Kuhl E. Modeling pathologies of diastolic and systolic heart failure // Ann. Biomed. Eng. 22016; 44, (1): 112– 127. doi: 10.1007/s10439-015-1351-2.
30. Bespalova I.D., Kalyuzhin V.V., Medjancev Ju.A. Kachestvo zhizni bol’nyh ishemicheskoj bolezn’ju serdca: vzaimosvjaz’ s komponentami metabolicheskogo sindroma i markerami sistemnogo vospalenija [Quality of life in patients with coronary heart disease: relationship with metabolic syndrome components and markers of systemic inflammation] // Byulleten’ sibirskoy meditsiny – Bulletin of Siberian Medicine. 2012; 11 (6): 17–20. (in Russian).
31. Calafiore A.M., Iacò A.L., Abukoudair W., Penco M., Di Mauro M. Left ventricular surgical remodeling after the STICH trial // Thorac. Cardiovasc. Surg. 2011; 59 (4): 95–200. doi: 10.1055/s-0030-1270738.
32. Dor V. Surgical remodeling of left ventricle // Surg. Clin. North Am. 2004; 84 (1): 27–43.
33. Wallen W.J., Rao V. Surgical remodeling of the left ventricle in heart failure // Ann. Thorac. Cardiovasc. Surg. 2010; 16 (2): 72–77.
34. Athanasuleas C.L., Buckberg G. Surgical ventricular restoration: where do we go from here? // Heart Fail. Rev. 2015; 20 (1): 89–93. doi: 10.1007/s10741-014-9433-z.
35. Bokerija L.A., Bokerija O.L., Le T.G. Jelektrofiziologicheskoe remodelirovanie miokarda pri serdechnoj nedostatochnosti i razlichnyh zabolevanijah serdca [Electrophysiological remodeling of myocardium in heart failure and various heart diseases] // Annaly aritmologii. 2010; 7 (4): 41–48 (in Russian).
36. Goluhova E.Z., Mashina T.V., Kakuchaja T.T., Kruglova M.V., Sin’kovskaja E.S., Mrikaev D.V. Stukturno-funkcional’noe i jelektrofiziologicheskoe remodelirovanie levogo zheludochka u pacientov s ishemicheskoj bolezn’ju serdca, oslozhnennoj serdechnoj nedostatochnost’ju [Stucture- functional, and electrophysiological remodeling of the left ventricle in patients with ischemic heart disease complicated by heart failure] // Bjulleten’ NCSSH im. A.N. Bakuleva RAMN. Serdechno-sosudistye zabolevanija. 2008; 9 (S6): 280 (in Russian).
37. Opie L.H., Commerford P.J., Gersh B.J., Pfeffer M.A. Controversies in ventricular remodelling // Lancet. 2006; 367 (9507): 356–367.
38. Shah A.M., Pfeffer M.A. Left ventricular size, mass, and shape: is the sum greater than the parts? // JACC Heart Fail. 2014; 2 (5): 523–525. doi: 10.1016/j.jchf.2014.05.010.
39. Belenkov Ju.N. Remodelirovanie levogo zheludochka. Dolzhny li my rasshirit’ ili suzit’ koncepciju? [Remodeling of the left ventricle. Should we expand or narrow concept?]. Sovremennye principy lechenija koronarnoj nedostatochnosti i ee oslozhnenij: materialy simpoziuma. M., 1996: 6–7. (in Russian).
40. Balakumar P., Jagadeesh G. Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared? // Pharmacol Res. 2010; 62 (5): 365– 383. doi: 10.1016/j.phrs.2010.07.003.
41. González A., Ravassa S., Beaumont J., Lуpez B., Dнez J. New targets to treat the structural remodeling of the myocardium // J. Am. Coll. Cardiol. 2011; 58 (18): 1833–1843. doi: 10.1016/j.jacc.2011.06.058.
42. Libbi P., Bonnow R.O., Mann D.L., Zajps D.P. Bolezni serdca po Braunval’du. Rukovodstvo po serdechno-so-sudistoj medicine. In 4 volumes, vol. 2. Moscow: Logosfera Publ., 2012: 526 (in Russian).
43. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly // Annu. Rev. Physiol. 2003; 65 (1): 45–79.
44. Lu C., Wang X., Ha T., Hu Y., Liu L., Zhang X., Yu H., Miao J., Kao R., Kalbfleisch J., Williams D., Li C. Attenuation of cardiac dysfunction and remodeling of myocardial infarction by microRNA-130a are mediated by suppression of PTEN and activation of PI3K dependent signaling // J. Mol. Cell. Cardiol. 2015; 89 (Pt A): 87–97. doi: 10.1016/j.yjmcc.2015.10.011.
45. Wang A.W., Song L., Miao J., Wang H.X., Tian C., Jiang X., Han Q.Y., Yu L., Liu Y., Du J., Xia Y.L., Li H.H. Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-κB, and calcineurin signaling pathways in mice // Am. J. Hypertens. 2015; 28 (4): 518–526. doi: 10.1093/ajh/hpu194.
46. Sankar N., deTombe P.P., Mignery G.A. Calcineurin-NFATc regulates type 2 inositol 1,4,5-trisphosphate receptor (InsP3R2) expression during cardiac remodeling // J. Biol. Chem. 2014; 289 (9): 6188–6198. doi: 10.1074/jbc.M113.495242.
47. Bisserier M., Berthouze-Duquesnes M., Breckler M., Tortosa F., Fazal L., de Régibus A., Laurent A.C., Varin A., Lucas A., Branchereau M., Marck P., Schickel J.N., Deloménie C., Cazorla O., Soulas-Sprauel P., Crozatier B., Morel E., Heymes C., Lezoualc’h F. Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling // Circulation. 2015; 131 (4): 390–400. doi: 10.1161/CIRCULATIONAHA.114.010686.
48. Zhang M., Hagenmueller M., Riffel J.H., Kreusser M.M., Bernhold E., Fan J., Katus H.A., Backs J., Hardt S.E. Calcium/calmodulin-dependent protein kinase II couples Wnt signaling with histone deacetylase 4 and mediates dishevelled-induced cardiomyopathy // Hypertension. 2015; 65 (2): 335–344. doi: 10.1161/HYPERTENSIONAHA.114.04467.
49. Toischer K., Rokita A.G., Unsцld B., Zhu W., Kararigas G., Sossalla S., Reuter S.P., Becker A., Teucher N., Seidler T., Grebe C., Preuss L., Gupta S.N., Schmidt K., Lehnart S.E., Krüger M., Linke W.A., Backs J., Regitz-Zagrosek V., Schäfer K., Field L.J., Maier L.S., Hasenfuss G. Differential cardiac remodeling in preload versus afterload // Circulation. 2010; 122 (10): 993–1003. doi: 10.1161/CIRCULATIONAHA.110.943431.
50. Lighthouse J.K., Small E.M. Transcriptional control of cardiac fibroblast plasticity // J. Mol. Cell. Cardiol. 2016; 91: 52–60. doi: 10.1016/j.yjmcc.2015.12.016.
51. Huby A.C., Turdi S., James J., Towbin J.A., Purevjav E. FasL expression in cardiomyocytes activates the ERK1/2 pathway, leading to dilated cardiomyopathy and advanced heart failure // Clin. Sci. (Lond). 2016; 130 (4): 289–299. doi: 10.1042/CS20150624.
52. Oka T., Morita H., Komuro I. Novel molecular mechanisms and regeneration therapy for heart failure // J. Mol. Cell. Cardiol. 2016; 92: 46–51. doi: 10.1016/j.yjmcc.2016.01.028.
53. Passariello C.L., Li J., Dodge-Kafka K., Kapiloff M.S. mAKAP-a master scaffold for cardiac remodeling // J. Cardiovasc. Pharmacol. 2015; 65 (3): 218–225. doi: 10.1097/FJC.0000000000000206.
54. Yu W., Huang X., Tian X., Zhang H., He L., Wang Y., Nie Y., Hu S., Lin Z., Zhou B., Pu W., Lui K.O., Zhou B. GATA4 regulates Fgf16 to promote heart repair after injury // Development. 2016; 143 (6): 936–949. doi: 10.1242/dev.130971.
55. Li Q., Guo Z.K., Chang Y.Q., Yu X., Li C.X., Li H. Gata4, Tbx5 and Baf60c induce differentiation of adipose tissue-derived mesenchymal stem cells into beating cardiomyocytes // Int. J. Biochem. Cell. Biol. 2015; 66: 30–36. doi: 10.1016/j.biocel.2015.06.008.
56. Zhang Y., Storey K.B. Expression of nuclear factor of activated T cells (NFAT) and downstream muscle-specific proteins in ground squirrel skeletal and heart muscle during hibernation // Mol. Cell. Biochem. 2016; 412 (1–2): 27–40. doi: 10.1007/s11010-015-2605-x.
57. Chien P.T., Lin C.C., Hsiao L.D, Yang C.M. c-Src/Pyk2/EGFR/PI3K/Akt/CREB- activated pathway contributes to human cardiomyocyte hypertrophy: Role of COX-2 induction // Mol. Cell. Endocrinol. 2015; 409: 59–72.
58. Kohli S., Ahuja S., Rani V. Transcription factors in heart: promising therapeutic targets in cardiac hypertrophy // Curr Cardiol Rev. 2011; 7 (4): 262– 271.
59. Chistiakov D.A., Orekhov A.N., Bobryshev Y.V. Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction) // J. Mol. Cel.l Cardiol. 2016; 94: 107–121. doi: 10.1016/j.yjmcc.2016.03.015.
60. Gurha P. MicroRNAs in cardiovascular disease // Curr. Opin. Cardiol. 2016; 31 (3): 249–254. doi: 10.1097/HCO.0000000000000280.
61. Taegtmeyer H., Sen S., Vela D. Return to the fetal gene program: A suggested metabolic link to gene expression in the heart // Ann. NY. Acad. Sci. 2010; 1188: 191– 198. doi:10.1111/j.1749-6632.2009.05100.x.
62. Carreсo J.E., Apablaza F., Ocaranza M.P.,. Jalil J.E. Cardiac hypertrophy: molecular and cellular events // Rev. Esp. Cardiol. 2006; 59 (5): 473–486.
63. Hill J.A., Olson E.N. Cardiac plasticity // N. Engl. J. Med. 2008; 358: 1370– 1380.
64. Li N., Wang C., Jia1 L., Du J. Heart regeneration, stem cells, and cytokines // Regenerative Medicine Research. 2014; 2: 6. doi:10.1186/2050-490X-2-6.
65. Szibor M., Pцling J., Warnecke H., Kubin T., Braun T. Remodeling and dedifferentiation of adult cardiomyocytes during disease and regeneration // Cell. Mol. Life. Sci. 2014; 71 (10): 1907–1916. doi: 10.1007/s00018-013-1535-6.
66. Lang R.M., Bierig M., Devereux R.B. и др. 2012; 3 (95). Приложение 1. (in Russian).
67. Shiller N., Osipov M.A. Klinicheskaja jehokardiografija [Clinical echocardiography]. Moscow, 1993: 347 (in Russian).
68. Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., Flachskampf F.A., Foster E., Goldstein S.A., Kuznetsova T., Lancellotti P., Muraru D., Picard M.H., Rietzschel E.R., Rudski L., Spencer K.T., Tsang W., Voigt J-U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging // European Heart Journal – Cardiovascular Imaging. 2015; 16: 233–271. doi:10.1093/ehjci/jev014
69. Savage D.D., Garrison M.S., Kannel W.B., Levy D., Anderson S.J., Stokes J. 3rd, Feinleib M., Castelli W.P. The spectrum of left ventricular hypertrophy in a general opulation sample: The Framingham Study // Circulation. 1987; 75 1 (Pt 2): I-26–I-33.
70. Shevchenko Ju.L., Bobrov L.L., Obrezan A.G. Diastolicheskaja funkcija levogo zheludochka [Diastolic function of the left ventricle]. Moscow, «GEOTAR-Media» Publ., 2002: 240 (in Russian).
71. Khouri M.G., Peshock R.M., Ayers C.R., de Lemos J.A., Drazner M.H. A 4-tiered сlassification of left ventricular hypertrophy based on left ventricular geometry. The Dallas Heart Study // Circ. Cardiovasc. Imaging. 2010; 3: 164–171. doi: 10.1161/CIRCIMAGING.109.883652
72. Mareev V.Ju., Ageev F.T., Arutjunov G.P., Koroteev A.V., Mareev Ju.V., Ovchinnikov A.G., Belenkov Ju.N., Vasjuk Ju.A., Galjavich A.S., Garganeeva A.A., Giljarevskij S.R., Glezer M.G., Drapkina O.M., Koziolova N.A., Koc Ja.I., Lopatin Ju.M., Martynov A.I., Moiseev V.S., Revishvili A.Sh., Sitnikova M.Ju., Skibickij V.V., Sokolov E.I., Storozhakov G.I., Fo-min I.V., Chesnikova A.I., Shljahto E.V. Nacional’nye rekomendacii OSSN, RKO i RNMOT po diagnostike i lecheniju HSN (chetvertyj peresmotr) [National recommendations OSSN, RKO and RNMOT on the diagnosis and treatment of chronic heart failure (fourth revision)] // Zhurnal serdechnaja nedostatochnost’. 2013; 14 (7, 81): 1–94. (in Russian).
73. Jugditt B.I. Nitrates and left ventricular remodeling //Am. J. Cardiol. 1998; 81: 57A–67A.
74. Petrova E.B., Statkevich T.V., Ponomarenko I.N., Mit’kovskaja N.P. Postinfarktnoe remodelirovanie levogo zheludochka: nekotorye patogeneticheskie aspekty [Postinfarction remodeling of the left ventricle: some pathogenetic aspects] // Voennaja medicina. 2015; 1 (34): 116–122.
75. Westman P.C., Lipinski M.J., Luger D., Waksman R., Bonow R.O., Wu E., Epstein S.E. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction // J. Am. Coll. Cardiol. 2016; 67 (17): 2050–2060. doi: 10.1016/j.jacc.2016.01.073.
76. Uematsu M., Yoshizaki T., Shimizu T., Obata J.E., Nakamura T., Fujioka D., Watanabe K., Watanabe Y., Kugiyama K. Sustained myocardial production of stromal cell-derived factor-1α was associated with left ventricular adverse remodeling in patients with myocardial infarction // Am. J. Physiol. Heart. Circ. Physiol. 2015; 309 (10):H1764–H1771. doi: 10.1152/ajpheart.00493.2015
77. Teplyakov A.T., Popov S.V., Kalyuzhin V.V., Garganeeva A.A., Kurlov I.O., Nilogov V.L., Rybal’chenko E.V., Shilov S.I. Ocenka vlijanija karvedilola, atenolola i ih kombinacii s fozinoprilom na variabel’nost’ ritma serdca, kliniko- funkcional’nyj status i kachestvo zhizni bol’nyh s postinfarktnoj disfunkciej levogo zheludochka [Evaluation of the effect of carvedilol, atenolol and their combination with fosinopril on heart rate variability, clinical and functional status and quality of life in patients with postinfarction left ventricular dysfunction] // Terapevticheskiy Arkhiv – Therapeutic archive. 2004; 76 (9): 62–65 (in Russian).
78. Neves J.S., Leite-Moreira A.M., Neiva-Sousa M., Almeida-Coelho J., Castro- Ferreira R., Leite-Moreira A.F. Acute myocardial response to stretch: what we (don’t) know // Front. Physiol. 2016; 6: article 408. doi: 10.3389/fphys.2015.00408.
79. Teplyakov A.T., Pushnikova E.Ju., Andrijanova A.V., Kalyuzhin V.V., Suslova T.E., Nikonova E.N., Karpov R.S. Miokardial’naja i arterial’naja zhestkost’ — vazhnaja determinanta jekspressii N-koncevogo predshestvennika mozgovogo natrijureticheskogo peptida pri razvitii serdechnoj nedostatochnosti u pacientov, perenesshih infarkt miokarda [Myocardial and arterial stiffness, an important determinant in the expression of N-terminal precursor of brain natriuretic peptide in the development of heart failure in patients with myocardial infarction] // Kardiologiya. 2016; 56 (4): 42–48. doi: http://dx.doi.org/10.18565/cardio.2016.4.42- 48.
80. Tarasov N.I., Teplyakov A.T., Malahovich E.V., Stepacheva T.A., Fedosova N.N., Kalyuzhin V.V., Pushnikova E.Ju. Sostojanie perekisnogo okislenija lipidov, antioksidantnoj zashhity krovi u bol’nyh infarktom miokarda, otjagoshhennym nedostatochnost’ju krovoobrashhenija [The status of lipid peroxidation, blood antioxidant protection in patients with myocardial infarction, burdened with circulatory insufficiency] // Terapevticheskiy Arkhiv – Therapeutic archive. 2002; 74 (12): 12–15 (in Russian).
81. Kuznecov V.A., Jaroslavskaja E.I., Pushkarev G.S., Krinochkin D.V., Zyrjanov I.P., Mar’inskih L.V. Hronicheskaja mitral’naja regurgitacija u zhenshhin s IBS i postinfarktnym kardiosklerozom [Chronic mitral regurgitation in women with IHD and postinfarction cardiosclerosis] // Rossijskij kardiologicheskij zhurnal. 2013; 2 (100): 18–23.
82. Kron I.L., Acker M.A., Adams D.H., Ailawadi G., Bolling S.F., Hung J.W., Lim D.S., LaPar D.J., Mack M.J., O’Gara P.T., Parides M.K., Puskas J.D. 2015 The American Association for Thoracic Surgery Consensus Guidelines: Ischemic mitral valve regurgitation // J. Thorac.Cardiovasc. Surg. 2016; 151 (4): 940–956. doi: 10.1016/j.jtcvs.2015.08.127.
83. Mezhdunarodnoe rukovodstvo po serdechnoj nedostatochnosti [International guidelines on heart failure]. / edited by S.G. Boll, R.V.F. Campbell, G.S. Francis; trans. from english. Moscow, MEDIA SFERA Publ., 1995: 89 (in Russian).
84. Grossman W., Paulus W.J. Myocardial stress and hypertrophy: a complex interface between biophysics and cardiac remodeling // J. Clin. Invest. 2013; 123 (9): 3701– 3703. doi:10.1172/JCI69830.
85. Shljahto E.V., Konradi A.O. Remodelirovanie serdca pri gipertonicheskoj bolezni [Cardiac remodeling in hypertension] // Zhurnal Serdce – Russian Heart Journal. 2002; 1 (5): 232–235 (in Russian).
86. Coutinho T., Pellikka P.A., Bailey K.R., Turner S.T., Kullo I.J. Sex differences in the associations of hemodynamic load with left ventricular hypertrophy and concentric remodeling // Am. J. Hypertens. 2016; 29 (1): 73–80. doi: 10.1093/ajh/hpv071.
87. Wang S., Song K., Guo X., Xue H., Wang N., Chen J., Zou Y., Sun K., Wang H., He J., Hui R. The association of metabolic syndrome with left ventricular mass and geometry in community-based hypertensive patients among Han Chinese // J. Res. Med. Sci. 2015; 20 (10): 963–968. doi: 10.4103/1735-1995.172785
88. Solanki P., Zakir R.M., Patel R.J., Pentakota S.R., Maher J., Gerula C., Saric M., Kaluski E., Klapholz M. Hypertension in African Americans with heart failure: progression from hypertrophy to dilatation; perhaps not // High Blood Press. Cardiovasc. Prev. 2015; 22: 61–68. doi:10.1007/s40292-014-0070-3.
89. Carabello B.A. Volume overload // Heart Fail. Clin. 2012; 8 (1): 33–42. doi: 10.1016/j.hfc.2011.08.013.
90. Barnes J., DellʼItalia L.J. The multiple mechanistic faces of a pure volume overload: implications for therapy // Am. J. Med. Sci. 2014; 348 (4): 337–346. doi: 10.1097/MAJ.0000000000000255.
91. Japp A.G., Gulati A., Cook S.A., Cowie M.R., Prasad S.K. The Diagnosis and Evaluation of Dilated Cardiomyopathy // J. Am. Coll. Cardiol. 2016; 67 (25): 2996– 3010.doi: 10.1016/j.jacc.2016.03.590
92. Amorim S., Campelo M., Martins E., Moura B., Sousa A., Pinho T., Silva-Cardoso J., Maciel M.J. Prevalence, predictors and prognosis of ventricular reverse remodeling in idiopathic dilated cardiomyopathy // Rev. Port. Cardiol. 2016; 35 (5): 253–260. doi: 10.1016/j.repc.2015. 11.014.
93. Baxi A.J., Restrepo C.S., Vargas D., Marmol-Velez A., Ocazionez D., Murillo H. Hypertrophic cardiomyopathy from A to Z: genetics, pathophysiology, imaging, and management // Radiographics. 2016; 36 (2): 335–354. doi: 10.1148/rg.2016150137.
94. Travers J.G., Kamal F.A., Robbins J., Yutzey K.E., Blaxall B.C. Cardiac Fibrosis: The Fibroblast Awakens // Circ. Res. 2016; 118 (6): 1021–1040. doi: 10.1161/CIRCRESAHA.115.306565.
95. Lighthouse J.K., Small E.M. Transcriptional control of cardiac fibroblast plasticity // J. Mol. Cell. Cardiol.2016; 91: 52–60. doi: 10.1016/j.yjmcc.2015.12.016
96. Chang C.W., Dalgliesh A.J., Lуpez J.E., Griffiths L.G. Cardiac extracellular matrix proteomics: Challenges, techniques, and clinical implications // Proteomics Clin. Appl. 2016; 10 (1): 39–50. doi: 10.1002/prca.201500030.
Review
For citations:
Kalyuzhin V.V., Teplyakov A.T., Solovtsov M.A., Kalyuzhina E.V., Bespalova I.D., Terentyeva N.N. REMODELING OF THE LEFT VENTRICLE: ONE OR SEVERAL SCENARIOS? Bulletin of Siberian Medicine. 2016;15(4):120-139. (In Russ.) https://doi.org/10.20538/1682-0363-2016-4-120-139
Views:
2612
Email this article 